Compare MMYT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | CRNX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 2010 | 2018 |
| Metric | MMYT | CRNX |
|---|---|---|
| Price | $43.39 | $36.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $101.00 | $76.75 |
| AVG Volume (30 Days) | 896.9K | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $16.83 | $720.10 |
| Revenue Next Year | $17.24 | $184.67 |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.67 | $25.83 |
| 52 Week High | $105.23 | $57.99 |
| Indicator | MMYT | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 44.48 |
| Support Level | $32.67 | $33.19 |
| Resistance Level | $51.24 | $37.23 |
| Average True Range (ATR) | 2.31 | 2.32 |
| MACD | -0.57 | -0.44 |
| Stochastic Oscillator | 35.27 | 26.31 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.